Impact of Comorbidities on Survival Among Patients with Chronic Myeloid Leukaemia Using the Charlson Comorbidity Index: Retrospective study from Basra, Iraq
Journal Title: Sultan Qaboos University Medical Journal - Year 2019, Vol 19, Issue 3
Abstract
Objectives: In chronic diseases, comorbidities are known to have a strong negative association with overall survival (OS). This study aimed to use the Charlson Comorbidity Index (CCI) to examine the effect of comorbidities on OS among patients with chronic myeloid leukaemia (CML) treated with tyrosine kinase inhibitors. Methods: This retrospective study was conducted between January 2006 and October 2016 and included 247 CML patients treated at the Basra Oncology & Haematology Centre, Basra, Iraq. Information from hospital records was used to calculate CCI scores and patients were divided into groups based on scores of 2–3 (CCI1 group) or ≥4 (CCI2 group). The OS was calculated using Kaplan-Meier curves. Results: There were 177 (71.7%) patients in the CCI1 group and 70 (28.3%) in the CCI2 group. Overall, patients in the CCI1 group were significantly younger compared to those in the CCI2 group (median age: 35 versus 60 years; P <0.001); however, the gender distribution was similar in both groups (male-to-female ratio of 1:1.06 versus 1:1.18, respectively; P = 0.683). Diabetes mellitus was the most common comorbidity (17%), followed by hypertension (12%) and gastrointestinal diseases (6%). There were no significant differences in mortality between the groups (9.6% versus 8.6%; P = 0.801). In total, 69.6% of all deaths were related to CML progression rather than to the presence of comorbidities. Conclusion: No significant correlation was found between CCI score and OS among CML patients in Basra. However, larger long-term prospective studies are needed to evaluate associations with median age at diagnosis and disease severity and to develop region-specific prognostic scales.
Authors and Affiliations
Rafid A. Abood, Hasson M. Hasson, Asaad A. Khalaf, Elaf M. Saleh
Keywords
Related Articles
- EP ID EP168062
- DOI http://dx.doi.org/10.18295/squmj.2019.19.03.010
- Views 259
- Downloads 0
Therapy with radionuclides, clinical acceptance is overdue
In this issue, Drs. Bererhi and Constable‘ have published an important paper on the radiation doses received by relatives of patients after radioiodine therapy for thyroid cancer or for hyperthyroid Graves' disease. Ba...
Perinatal Outcome in Pregnancies with Extreme Preterm Premature Rupture of Membranes (Mid-Trimester PROM)
Objectives: Preterm premature rupture of membranes (PPROM) is defned as the rupture of fetal membranes before 37 weeks. Extreme PPROM occurs before 26 weeks’ gestation and can result in perinatal morbidity and mortal...
Harrison’s Neurology in Clinical Medicine
Rare Presentation of Aggressive T/Natural Killer Lymphoproliferative Disorder in a Leukaemic Phase in an Omani Patient
Reasons for Consultation among Patients attending Primary Healthcare Centres in Oman
Objectives: Pathways to care or care-seeking, which translate into healthcare utilisation, have been investigated in many parts of the world, but there is a dearth of studies in the Arabian Gulf. Te aim of this study w...